Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 18/20 | 0.62 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | MMP7 | P09237 | 1/20 | 0.46 |
| ▸ | MMP10 | P09238 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6790405 | 0.92 | ADAM17 (0.70) | ADAM17MMP3MMP7MMP10MMP2 | |
| SCHEMBL6797151 | 0.85 | ADAM17 (0.61) | ADAM17MMP3MMP7MMP10MMP2 | |
| SCHEMBL6259435 | 0.80 | ADAM17 (0.80) | ADAM17MMP3MMP7MMP10 | |
| SCHEMBL6279181 | 0.80 | ADAM17 (0.80) | ADAM17MMP3MMP7MMP10 | |
| SCHEMBL6259432 | 0.80 | ADAM17 (0.80) | ADAM17MMP3MMP7MMP10 | |
| SCHEMBL6790903 | 0.80 | ADAM17 (0.79) | ADAM17MMP3MMP7MMP10MMP2 | |
| SCHEMBL6791676 | 0.79 | ADAM17 (0.86) | ADAM17MMP3MMP7MMP10MMP2 | |
| SCHEMBL6797248 | 0.79 | ADAM17 (0.61) | ADAM17MMP3MMP7MMP10MMP2 | |
| SCHEMBL6796124 | 0.78 | ADAM17 (0.86) | ADAM17MMP3MMP7MMP10 | |
| SCHEMBL6797882 | 0.78 | ADAM17 (0.70) | ADAM17MMP3MMP7MMP10MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6740649-B2 | ANTIINFLAMMATORY AGENTS; OSTEOPOROSIS | BRISTOL-MYERS SQUIBB COMPANY | 2004-05-25 | — | — | US | disclosed |
| US-20030139388-A1 | Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139388-A1 | Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | ADAMTS1, MMP1, ADAM17 | ADAM17 3/4885MMP3 16/4885MMP7 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.